share_log

Redhill Biopharma | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Redhill Biopharma | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Redhill Biopharma | 6-K：外國發行人報告
SEC announcement ·  03/14 16:08
Moomoo AI 已提取核心訊息
RedHill Biopharma Ltd., a specialty biopharmaceutical company, has received a notification from the Nasdaq Listings Qualifications Department on March 11, 2024, indicating that the company's American Depositary Shares (ADSs) have been trading below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market for the past thirty consecutive business days. This notice does not immediately affect the listing or trading of RedHill's ADSs. The company has until September 9, 2024, to regain compliance with the minimum bid price requirement, as per Nasdaq Listing Rule 5810(c)(3)(A). RedHill's ADSs will continue to trade on The Nasdaq Capital Market, and its operations remain unaffected. RedHill is considering options to address the deficiency and may be eligible for an additional 180-day compliance period if necessary conditions are met.
RedHill Biopharma Ltd., a specialty biopharmaceutical company, has received a notification from the Nasdaq Listings Qualifications Department on March 11, 2024, indicating that the company's American Depositary Shares (ADSs) have been trading below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market for the past thirty consecutive business days. This notice does not immediately affect the listing or trading of RedHill's ADSs. The company has until September 9, 2024, to regain compliance with the minimum bid price requirement, as per Nasdaq Listing Rule 5810(c)(3)(A). RedHill's ADSs will continue to trade on The Nasdaq Capital Market, and its operations remain unaffected. RedHill is considering options to address the deficiency and may be eligible for an additional 180-day compliance period if necessary conditions are met.
專業生物製藥公司RedHill Biopharma Ltd. 已於2024年3月11日收到納斯達克上市資格部門的通知，表明該公司的美國存托股票（ADS）在過去連續三十個工作日中一直低於繼續在納斯達克資本市場上市的每股1.00美元的最低要求。本通知不會立即影響RedHill廣告的上市或交易。根據納斯達克上市規則第5810（c）（3）（A），該公司必須在2024年9月9日之前重新遵守最低出價要求。RedHill的ADS將繼續在納斯達克資本市場上交易，其業務不受影響。RedHill正在考慮解決這一缺陷的備選方案，如果滿足必要條件，可能有資格再延長180天的合規期。
專業生物製藥公司RedHill Biopharma Ltd. 已於2024年3月11日收到納斯達克上市資格部門的通知，表明該公司的美國存托股票（ADS）在過去連續三十個工作日中一直低於繼續在納斯達克資本市場上市的每股1.00美元的最低要求。本通知不會立即影響RedHill廣告的上市或交易。根據納斯達克上市規則第5810（c）（3）（A），該公司必須在2024年9月9日之前重新遵守最低出價要求。RedHill的ADS將繼續在納斯達克資本市場上交易，其業務不受影響。RedHill正在考慮解決這一缺陷的備選方案，如果滿足必要條件，可能有資格再延長180天的合規期。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息